Reuters logo
BRIEF-Aurinia Pharmaceuticals releases additional 48-week data from AURA-LV study
April 20, 2017 / 9:21 PM / 6 months ago

BRIEF-Aurinia Pharmaceuticals releases additional 48-week data from AURA-LV study

April 20 (Reuters) - Aurinia Pharmaceuticals Inc

* Aurinia releases additional 48-week data from the AURA-LV study during late-breaking session at the National Kidney Foundation 2017 spring clinical meetings

* Aurinia Pharmaceuticals Inc - 100% of patients in complete remission at week 24 stay in complete remission at week 48 while on low-dose voclosporin

* Aurinia Pharmaceuticals Inc - no unexpected safety signals were observed and voclosporin was generally well-tolerated from AURA-LV study Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below